middle.news
FDA Clears Neurizon’s NUZ-001 for Pivotal ALS Trial in Late 2025
9:03am on Monday 6th of October, 2025 AEDT
•
Biotechnology
Read Story
FDA Clears Neurizon’s NUZ-001 for Pivotal ALS Trial in Late 2025
9:03am on Monday 6th of October, 2025 AEDT
Key Points
FDA lifts clinical hold on NUZ-001, Neurizon’s lead ALS therapy
Entry into HEALEY ALS Platform Trial expected in Q4 2025
IND supported by strong preclinical safety and Elanco licensing data
Regulatory clearance accelerates development and partnering potential
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
NEURIZON THERAPEUTICS (ASX:NUZ)
OPEN ARTICLE